The role of transplant in the era of new treatments for lymphoma and CLL
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Overview of the Infectious Diseases Working Party
The IFM 2012-03 trial: what will the next step be?
The use of trastuzumab and biosimilars in the treatment of breast cancer